- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about VALN
Recent news which mentions VALN
Why Pfizer Stock Rose Today While the Market Tanked
April 26, 2022
From Motley Fool
From Benzinga
From Benzinga
China’s latest COVID outbreak spooks investors, and U.S. cases and hospitalizations are rising again
April 25, 2022
Tickers
VALN
Tags
VALN
From MarketWatch
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 25, 2022
From Benzinga
Valneva Receives More Questions From European Regulator For Its COVID-19 Vaccine, Shares Fall
April 25, 2022
From Benzinga
From Benzinga
From Benzinga
Earnings Scheduled For March 24, 2022
March 24, 2022
From Benzinga
From Benzinga
From Benzinga
76 Biggest Movers From Yesterday
March 08, 2022
From Benzinga
46 Stocks Moving In Monday's Mid-Day Session
March 07, 2022
From Benzinga
42 Stocks Moving in Monday's Pre-Market Session
March 07, 2022
From Benzinga
From Benzinga
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
February 25, 2022
From Benzinga
Valneva Secures £20M From Scottish Enterprise For Vaccine Development
February 22, 2022
Tickers
VALN
From Benzinga
Valneva - Pfizer Choose Three-Dose Schedule For Lyme Vaccine Candidate Moving Forward
February 04, 2022
From Benzinga
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
February 04, 2022
From Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
February 03, 2022
From Benzinga
From InvestorPlace
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
February 01, 2022
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.